Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | PRKDC | P78527 | 1/20 | 0.42 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ERN1 | O75460 | 6/20 | 0.35 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.35 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.33 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.33 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.33 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20157914 | 0.83 | LMNA (0.43) | LMNAPRKDCUHRF1ALDH1A1MAPT | |
| SCHEMBL22445258 | 0.79 | UHRF1 (0.39) | UHRF1CYP1A2CYP2A6 | |
| SCHEMBL6627536 | 0.78 | GRIA1 (0.44) | LMNAUHRF1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL29952665 | 0.78 | GRIA1 (0.44) | LMNAUHRF1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL19794988 | 0.78 | LMNA (0.41) | LMNAPRKDCALDH1A1MAPTHPGD | |
| SCHEMBL29411231 | 0.78 | LMNA (0.41) | LMNAPRKDCALDH1A1MAPTHPGD | |
| SCHEMBL14327941 | 0.75 | UHRF1 (0.54) | LMNAUHRF1ALDH1A1ERN1CYP1A2 | |
| SCHEMBL29953875 | 0.75 | CYP1A2 (0.38) | UHRF1ALDH1A1MAPTHPGDSMN1; SMN2 | |
| SCHEMBL9938111 | 0.75 | ERN1 (0.41) | LMNAPRKDCERN1TRIM24TRIM33 | |
| SCHEMBL29953878 | 0.75 | LMNA (0.39) | LMNAPRKDCERN1TRIM24TRIM33 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250195480-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | Fulcrum Therapeutics, Inc. | 2025-06-19 | — | — | US | disclosed |
| US-12109198-B2 | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators | Fulcrum Therapeutics, Inc. (US) | 2024-10-08 | — | — | US | disclosed |
| US-20240139163-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | Fulcrum Therapeutics, Inc. | 2024-05-02 | — | — | US | disclosed |
| CN-114144230-B | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators | 弗尔康医疗公司 | 2024-04-23 | — | — | CN | disclosed |
| US-11590111-B2 | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators | Fulcrum Therapeutics, Inc. (US) | 2023-02-28 | — | — | US | disclosed |
| US-20220160686-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | Fulcrum Therapeutics, Inc. | 2022-05-26 | — | — | US | disclosed |
| US-20220160686-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | Fulcrum Therapeutics, Inc. | 2022-05-26 | — | — | US | disclosed |
| CN-114144230-A | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators | 弗尔康医疗公司 | 2022-03-04 | — | — | CN | disclosed |
| EP-3938050-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | Fulcrum Therapeutics, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| US-10973805-B2 | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators | Fulcrum Therapeutics, Inc. (US) | 2021-04-13 | — | — | US | disclosed |
| US-10973805-B2 | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators | Fulcrum Therapeutics, Inc. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20200360353-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | Fulcrum Therapeutics, Inc. | 2020-11-19 | — | — | US | disclosed |
| US-20200360353-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | Fulcrum Therapeutics, Inc. | 2020-11-19 | — | — | US | disclosed |
| CN-111848502-A | Synthesis method of (5-bromo-2-methylpyridin-4-yl) methanol | 上海毕得医药科技有限公司 | 2020-10-30 | — | — | CN | disclosed |
| WO-2020190754-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | Fulcrum Therapeutics, Inc. (US) | 2020-09-24 | — | — | WO | disclosed |
| US-9346825-B2 | Fused bicyclic oxazolidinone CETP inhibitor | MERCK SHARP & DOHME CORP. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20140378493-A1 | Fused Bicyclic Oxazolidinone CETP Inhibitor | MERCK SHARP & DOHME LLC | 2014-12-25 | — | — | US | disclosed |
| US-8871738-B2 | Fused bicyclic oxazolidinone CETP inhibitor | MERCK SHARP & DOHME CORP. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20130109649-A1 | FUSED BICYCLIC OXAZOLIDINONE CETP INHIBITOR | MERCK SHARP & DOHME LLC | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10973805-B2 | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators | EED, EZH2, BMI1 | LMNA 2964/4885PRKDC 2044/4885UHRF1 222/4885 |
| US-12109198-B2 | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators | EED, EZH2, BMI1 | LMNA 2964/4885PRKDC 2044/4885UHRF1 222/4885 |
| US-20250195480-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | EED, EZH2, BMI1 | LMNA 2964/4885PRKDC 2044/4885UHRF1 222/4885 |
| US-20140378493-A1 | Fused Bicyclic Oxazolidinone CETP Inhibitor | CETP, MTTP, APOB | LMNA 555/4885PRKDC 2407/4885UHRF1 2239/4885 |
| US-20220160686-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | EED, EZH2, BMI1 | LMNA 2964/4885PRKDC 2044/4885UHRF1 222/4885 |
| US-20130109649-A1 | FUSED BICYCLIC OXAZOLIDINONE CETP INHIBITOR | CETP, MTTP, APOB | LMNA 555/4885PRKDC 2407/4885UHRF1 2239/4885 |
| US-11590111-B2 | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators | EED, EZH2, BMI1 | LMNA 2964/4885PRKDC 2044/4885UHRF1 222/4885 |
| US-20200360353-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | EED, EZH2, BMI1 | LMNA 3080/4885PRKDC 1921/4885UHRF1 205/4885 |
| US-20240139163-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | EED, EZH2, BMI1 | LMNA 2964/4885PRKDC 2044/4885UHRF1 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.